BCM
CLDX icon

Bayesian Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Bayesian Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,200
Closed -$470K – 790
2024
Q1 		$470K Buy
+11,200
New +$460K 0.04% 452
2022
Q4 		– Sell
-7,911
Closed -$222K – 815
2022
Q3 		$222K Sell
7,911
-4,589
-37% -$141K 0.05% 503
2022
Q2 		$337K Buy
+12,500
New +$363K 0.06% 434
2016
Q2 		– Sell
-907
Closed -$51K – 413
2016
Q1 		$51K Buy
+907
New +$102K 0.05% 330

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bayesian Capital Management's CLDX Position: Q2 2024 in Review

Bayesian Capital Management sold out of Celldex Therapeutics (CLDX) in Q2 2024, closing a stake of 11,200 shares — an estimated $470K sold.

Bayesian Capital Management first reported a position in CLDX in Q1 2016 and held it in 4 quarters. The position peaked at $470K in Q1 2024. 183 funds tracked by Wall St. Rank hold CLDX as of Q2 2024.

  • Bayesian Capital Management reported no remaining Celldex Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 11,200 Celldex Therapeutics shares in Q2 2024, an estimated $470K.
  • Bayesian Capital Management first reported a position in Celldex Therapeutics in Q1 2016 and held it in 4 quarters.
  • Bayesian Capital Management's Celldex Therapeutics position peaked at $470K in Q1 2024.
  • 183 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2024.

Based on Bayesian Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.